ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Yervoy